tirzepatide weight loss trial near me SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants New Trial Results Position Mounjaro
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4


















.jpg)









